EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy

Carlo Putzu, Riccardo Serra iD, Rachele Campus, Giovanni Maria Fadda, Claudio Sini, Andrea Marongiu iD, Giorgio Carlo Ginesu iD, Alessandro Giuseppe Fois iD, Giuseppe Palmieri iD, Angelo Zinellu iD, Antonio Cossu iD, Panagiotis Paliogiannis iD

Current Oncology · 2024

DOI: 10.3390/curroncol31090367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Carlo Putzu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Unit, University Hospital of Sassari (AOU SS), Via Enrico De Nicola 39, 07100 Sassari, Italy. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The aim of the study was to investigate a series of complete blood cell count-based biomarkers of systemic inflammation as predictors of clinical outcomes in patients who underwent first-line chemoimmunotherapy for advanced NSCLC.

Methods

Consecutive patients with pathologically diagnosed stage III/IV NSCLC and PD-L1 < 50% who underwent first-line chemoimmunotherapy were retrospectively enrolled. The clinical outcomes used for biomarker evaluation were Objective Response Rate (ORR) and Overall Survival (OS).

Results

Non-responders had significantly higher values of neutrophil to lymphocyte ratio (NLR, median: 5.36; IQR: 2.78–10.82 vs. 3.31; IQR: 2.15–4.12, p = 0.019), neutrophil to monocyte ratio (NMR, median: 14.00; IQR: 8.82–21.20 vs. 9.20; IQR: 7.45–11.20, p = 0.013), and systemic inflammation index (SII, median: 1395; IQR: 929–3334 vs. 945; IQR: 552–1373, p = 0.025), but only NLR and NMR remained independently associated with clinical response in multivariate logistic regression. In the univariate analysis, white blood cells (OR:1.2202; 95% CI: 1.0339–1.4400, p = 0.019), neutrophils (OR:1.2916; 95% CI: 1.0692–1.5604, p = 0.008), NLR (OR:1.3601: 95% CI: 1.0949–1.6896, p = 0.005) and NMR (OR:1.2159; 95% CI: 1.00396–1.4221, p = 0.015) were significantly associated with survival; Cox regression models confirmed that neutrophils, NLR, and MLR were independently associated with survival; NLR, at a cut-off value of 4.0, showed the better AUC (0.749) in predicting OS.

Conclusions

Baseline complete blood cell count biomarkers, especially the NLR, can predict clinical outcomes in patients with advanced NSCLC treated with first-line chemoimmunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenHumansFemaleMaleAgedMiddle AgedRetrospective StudiesBlood Cell CountImmunotherapyBiomarkers, TumorTreatment OutcomeNeutrophils

Stichwörter der Autor:innen

MNRNLRbiomarkersblood cell countchemotherapyimmunotherapylung cancer

Substanzen

B7-H1 AntigenCD274 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Medical Oncology Unit, University Hospital of Sassari (AOU SS), Via Enrico De Nicola 39, 07100 Sassari, Italy.
  • Specialty School of Medical Oncology, University of Cagliari, S.S. 554, Km 4500 Bivio per Sestu, 09042 Cagliari, Italy.
  • Specialty School in Pulmonology and Respiratory Diseases, University of Sassari, Viale San Pietro 43a, 07100 Sassari, Italy.
  • Medical Oncology Unit, Giovanni Paolo II Hospital of Olbia, Via Bazzoni Sircana 1, 07026 Olbia, Italy.
  • Department of Medicine, Surgery and Pharmacology, University of Sassari, Viale San Pietro 43a, 07100 Sassari, Italy.
  • Department of Biomedical Sciences, University of Sassari, Viale San Pietro 43a, 07100 Sassari, Italy.

ORCID-Profile: Riccardo Serra, Andrea Marongiu, Giorgio Carlo Ginesu, Alessandro Giuseppe Fois, Giuseppe Palmieri, Angelo Zinellu, Antonio Cossu, Panagiotis Paliogiannis

Zitieren

APA

Putzu, C., Serra, R., Campus, R., Fadda, G. M., Sini, C., Marongiu, A., Ginesu, G. C., Fois, A. G., Palmieri, G., Zinellu, A., Cossu, A., & Paliogiannis, P. (2024). Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy. Current Oncology. https://doi.org/10.3390/curroncol31090367

Vancouver

Putzu C, Serra R, Campus R, Fadda GM, Sini C, Marongiu A, et al. Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy. Current Oncology. 2024. doi:10.3390/curroncol31090367

BibTeX
@article{Putzu2024,
  author = {Putzu, Carlo and Serra, Riccardo and Campus, Rachele and Fadda, Giovanni Maria and Sini, Claudio and Marongiu, Andrea and Ginesu, Giorgio Carlo and Fois, Alessandro Giuseppe and Palmieri, Giuseppe and Zinellu, Angelo and Cossu, Antonio and Paliogiannis, Panagiotis},
  title = {Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31090367}
}
Kostenlos starten →